Circuit Reaffirms Invalidity of Pfizer's Norvasc Patent

Law360, New York (June 5, 2007, 12:00 AM EDT) -- A circuit court on Tuesday reaffirmed that a Pfizer Inc. patent for popular hypertension drug Norvasc is invalid by overturning a patent infringement ruling against Mylan Laboratories Inc.

The U.S. Court of Appeals for the Federal Circuit reversed a district court ruling that a launch of generic Norvasc, known as amlodine besylate, would infringe the Pfizer patent. District Judge Terrence F. McVerry of the U.S. District Court for the Western District of Pennsylvania had ruled in February that Pfizer's patent covering amlodine besylate was valid, enforceable...
To view the full article, register now.